Surface Logix closes Series E equity and debt financing

In its Series E financing round, Surface Logix (developing small-molecule therapeutics for metabolic and cardiovascular disorders) raised $15mm through the sale of equity to first-time backer MPM Capital and returning investors Arch Venture Partners (co-lead), HBM BioVentures (adds a board member), Healthcare Focus, Intel Capital, Saudi Venture Development Company, Unilever Technology Ventures, and Venrock Associates (co-lead). The company also sold $5mm in debt to Silicon Valley Bank. Surface Logix will use part of the funds for clinical trials of SLx4090 in dyslipidemia, diabetes, and obesity; SLx2101 for hypertension; and its lead ROCK inhibitor SLx2119.